39.29

0.77% +0.30

Structure Therapeutics Inc ADR (GPCR)

Overview News Price History Option Chain Financials Why GPCR Down? Discussions Forecast

Structure Therapeutics Inc ADR stock is currently priced at $39.29, with a 24-hour trading volume of 349.85K. It has seen a +0.77% increased in the last 24 hours and a -1.92% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $39.03 pivot point. If it approaches the $39.74 resistance level, significant changes may occur.

Previous Close:

$38.99

Open:

$39.55

24h Volume:

349.85K

Market Cap:

$1.83B

Revenue:

Net Income/Loss:

$-89.62M

P/E Ratio:

-18.29

EPS:

-2.1478

Net Cash Flow:

$-81.66M

1W Performance:

+0.90%

1M Performance:

-1.92%

6M Performance:

-43.78%

1Y Performance:

+62.02%

1D Range:

$39.20

$40.56

52W Range:

$21.79

$75.02

Structure Therapeutics Inc ADR Stock (GPCR) Company Profile

Name

Structure Therapeutics Inc ADR

Sector

Healthcare (1213)

Industry

Biotechnology (699)

Phone

628-229-9277

Address

611 Gateway Boulevard, Suite 223, South San Francisco

Employee

Twitter

Next Earnings Date

Latest SEC Filings

GPCR's Discussions on Twitter

Structure Therapeutics Inc ADR Stock (GPCR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-19-23	Initiated	JMP Securities	Mkt Outperform
Jul-27-23	Initiated	Piper Sandler	Overweight
May-25-23	Resumed	Jefferies	Buy
Feb-28-23	Initiated	BMO Capital Markets	Outperform
Feb-28-23	Initiated	Guggenheim	Buy
Feb-28-23	Initiated	Jefferies	Buy
Feb-28-23	Initiated	SVB Securities	Outperform

View All

Structure Therapeutics Inc ADR Stock (GPCR) Latest News

Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference

GlobeNewswire Inc.

Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights

GlobeNewswire Inc.

IPO Watch 2024: Which New Stocks Will Hit the Market?

Investing.com

Structure Therapeutics Stock Just Crashed. Here's Why It Could Be Worth Buying Now

The Motley Fool

Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?

MarketWatch

Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?

MarketWatch

Structure Therapeutics Inc ADR Stock (GPCR) Financials Data

Structure Therapeutics Inc ADR (GPCR) Net Income 2024

GPCR net income (TTM) was -$89.62 million for the quarter ending December 31, 2023, a -74.63% decrease year-over-year.

Structure Therapeutics Inc ADR (GPCR) Cash Flow 2024

GPCR recorded a free cash flow (TTM) of -$81.66 million for the quarter ending December 31, 2023, a -76.46% decrease year-over-year.

Structure Therapeutics Inc ADR (GPCR) Earnings per Share 2024

GPCR earnings per share (TTM) was -$2.46 for the quarter ending December 31, 2023, a -28.26% decline year-over-year.

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.